Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis
Table 2
Association of different clinical and pathological characteristics with neutrophil-to-lymphocyte ratio in patients with nonmetastatic renal cell carcinoma.
Variable
All
Low NLR
High NLR
value
Number of subjects
1,284
1,168
116
NLR, mean ± SD
<0.00
Age, mean ± SD, year
0.00
Gender
0.23
Male, n (%)
913 (71.1)
825 (70.6)
88 (75.9)
Female, n (%)
371 (28.9)
343 (29.4)
28 (24.1)
BMI, mean ± SD, kg/m2
0.00
ECOG PS ≥ 1, n (%)
180 (14.0)
148 (12.7)
32 (27.6)
<0.00
Symptoms at presentation
0.00
No symptom, n (%)
975 (75.9)
900 (77.1)
75 (64.7)
Symptom, n (%)
309 (24.1)
268 (22.9)
41 (35.3)
Tumor size
(1) mean ± SD, cm
<0.00
(2) Category
<0.00
<4 cm, n (%)
748 (58.3)
701 (60.0)
47 (40.5)
4–7 cm, n (%)
351 (27.3)
321 (27.5)
30 (25.9)
≥7 cm, n (%)
185 (14.4)
146 (12.5)
39 (33.6)
Side
1.00
Unilateral, n (%)
1,268 (98.8)
1,153 (98.7)
115 (99.1)
Bilateral, n (%)
16 (1.2)
15 (1.3)
1 (0.9)
Type of nephrectomy
<0.00
Radical, n (%)
634 (49.4)
552 (47.3)
82 (70.7)
Partial, n (%)
650 (50.6)
616 (52.7)
34 (29.3)
Method of surgery
0.04
Open, n (%)
697 (54.3)
628 (53.8)
69 (59.5)
Laparoscopic, n (%)
316 (24.6)
283 (24.2)
33 (28.4)
Robot, n (%)
271 (21.1)
257 (22.0)
14 (12.1)
T stage
<0.00
T1, n (%)
1,016 (79.1)
945 (80.9)
71 (61.2)
T2, n (%)
89 (6.9)
75 (6.4)
14 (12.1)
T3-4, n (%)
179 (13.9)
148 (12.7)
31 (26.7)
Fuhrman’s grade
0.56
G1-2, n (%)
664 (51.7)
607 (52.0)
57 (49.1)
G3-4, n (%)
620 (48.3)
561 (48.0)
59 (50.9)
Histologic subtype
0.04
Clear cell, n (%)
1,114 (86.8)
1,017 (87.1)
97 (83.6)
Papillary, n (%)
87 (6.8)
73 (6.3)
14 (12.1)
Chromophobe, n (%)
83 (6.5)
78 (6.7)
5 (4.3)
Sarcomatoid differentiation, yes, n (%)
29 (2.3)
22 (1.9)
7 (6.0)
0.00
Tumor necrosis, yes, n (%)
208 (16.2)
174 (14.9)
34 (29.3)
<0.00
Recurrence, n (%)
142 (11.1)
114 (9.8)
28 (24.1)
<0.00
RCC-specific death, n (%)
56 (4.4)
40 (3.4)
16 (13.8)
<0.00
NLR, neutrophil-to-lymphocyte ratio; low NLR, <3.7; high NLR, ≥3.7; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; RCC, renal cell carcinoma; n, number of subjects; SD, standard deviation. tudent t-test. earson’s chi-square test. isher’s exact test.
